Dr. Abida on Future of Hormonal Therapy in Prostate Cancer

Wassim Abida, MD, PhD
Published: Wednesday, Feb 01, 2017



Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Targeting androgen receptors (AR) is a topic being explored, specifically the parts of AR that are not already being targeted. There are other targets worth attention beyond the C-terminal ligand binding domain, says Abida.

These targets include AR-V7, but new drugs need to be developed that target the protein within it. According to Abida, that is worth exploring even though it is not known whether it will yield a response.

Combination therapy is also an approach that is being looked at as the future of hormonal therapy in prostate cancer.
 


Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Targeting androgen receptors (AR) is a topic being explored, specifically the parts of AR that are not already being targeted. There are other targets worth attention beyond the C-terminal ligand binding domain, says Abida.

These targets include AR-V7, but new drugs need to be developed that target the protein within it. According to Abida, that is worth exploring even though it is not known whether it will yield a response.

Combination therapy is also an approach that is being looked at as the future of hormonal therapy in prostate cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x